What Is Cosentyx, and Why Does It Matter? Cosentyx (secukinumab) is a fully human biologic medicine that targets and blocks interleukin‑17A (IL‑17A), a naturally occurring protein in the body that ...
Novartis is counting on Cosentyx's approval in hidradenitis suppurativa and other new uses to drive the med's next phase of growth. Cosentyx may soon share the hidradenitis suppurativa (HS) field with ...
Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the ...
In just the last quarter, the number of HS patients treated with biologics has increased 27% year over year. According to Spherix, that increase likely represents not only biologics’ grabbing market ...
Hosted on MSN
Novartis advances dermatology portfolio with Cosentyx FDA approval for pediatric patients
On Friday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s NVS Cosentyx (secukinumab) for younger patients. The approval covers pediatric patients 12 years and older with moderate ...
Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...
Approval was supported by adult HS and psoriasis clinical trials, pharmacokinetic modeling, and data from established pediatric indications. The Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results